Epigenetic mechanisms have gained relevance in human health and environmental studies, due to their pivotal role in disease, gene × environment interactions and adaptation to environmental change and/or contamination. Epigenetic mechanisms are highly responsive to external stimuli and a wide range of chemicals has been shown to determine specific epigenetic patterns in several organisms. Furthermore, the mitotic/meiotic inheritance of such epigenetic marks as well as the resulting changes in gene expression and cell/organismal phenotypes has now been demonstrated. Therefore, epigenetic signatures are interesting candidates for linking environmental exposures to disease as well as informing on past exposures to stressors. Accordingly, epigenetic biomarkers could be useful tools in both prospective and retrospective risk assessment but epigenetic endpoints are currently not yet incorporated into risk assessments. Achieving a better understanding on this apparent impasse, as well as identifying routes to promote the application of epigenetic biomarkers within environmental risk assessment frameworks are the objectives of this review. We first compile evidence from human health studies supporting the use of epigenetic exposure-associated changes as reliable biomarkers of exposure. Then, specifically focusing on environmental science, we examine the potential and challenges of developing epigenetic biomarkers for environmental fields, and discuss useful organisms and appropriate sequencing techniques to foster their development in this context. Finally, we discuss the practical incorporation of epigenetic biomarkers in the environmental risk assessment of chemicals, highlighting critical data gaps and making key recommendations for future research within a regulatory context.
Epigenetic mechanisms are those related to heritable modifications in gene activity, function and expression that do not involve changes in the underlying DNA sequence itself. There are three main epigenetic mechanisms: (i) DNA methylation, or the chemical modification of DNA bases through the addition or removal of methyl groups; (ii) histone modifications (protein modifications by, for example, methylation and acetylation) that constrain chromatin structure and DNA accessibility; and (iii) small non-coding RNAs that both control the expression of individual genes and also form complex regulatory networks of the genome, the two main categories being microRNAs (miRNAs) and small interfering RNAs (siRNAs). Variants of these three epigenetic mechanisms have also been described: DNA hydroxymethylation and variations in histone modification, as well as other mechanisms of post-transcriptional regulation such as nucleosome-space occupancy (Jaenisch & Bird, 2003; Bird, 2007; Turner, 2012; Wei et al., 2017) .
Epigenetic mechanisms are perhaps best known for their critical role in controlling and regulating the important molecular mechanism of transcription (Jaenisch & Bird, 2003; Bird, 2007; Barros & Offenbacher, 2009 ). However, epigenetic mechanisms are also involved in several other key molecular and cellular processes, such as tumourigenesis, development, chromosome inactivation, genomic imprinting and transposable element regulation (Engel, 2015; Galindo-González, Sarmiento & Quimbaya, 2018; Chatterjee, Rodger & Eccles, 2018a) . Furthermore, epigenetic mechanisms have a pivotal role in diverse medical and behavioural disorders including metabolic, mental and reproductive diseases and cancer (Nestler, 2014; Piletič & Kunej, 2016; Hawkins, Al-attar & Storey, 2018; Chatterjee et al., 2018a) . Considering this broad relevance of epigenetic mechanisms, the way they respond when challenged by external stimuli has been extensively scrutinised. Such research has revealed that a high number and wide range of toxicants, toxins and environmental cues can determine specific epigenetic marks/patterns (Baccarelli & Bollati, 2009; Feil & Fraga, 2012; Vandegehuchte & Janssen, 2014) . Importantly, some of these environmentally induced epigenetic marks/patterns have been demonstrated to be reversible when the environmental inducer is no longer present, but some can be mitotically/meiotically inherited through a process known as epigenetic transgenerational inheritance (Bird, 2002; Ho & Burggren, 2010; Walker, Kublin & Zunt, 2014; Blake & Watson, 2016; Burggren, 2016) . This phenomenon has been shown to occur in several organisms, including model species in diverse scientific fields (Rando, 2016; Kamstra et al., 2018; Trijau et al., 2018; Jeremias et al., 2018b) . As epigenetic mechanisms regulate gene expression, the consequence of a given environmental stressor in this context can be a change in the phenotype of cells and organisms (environmentally induced epigenetic phenotypes). Their inheritance through successive generations can ultimately lead to the induction of micro-evolutionary patterns in individual-and population-level traits (Burggren, 2016; Jeremias et al., 2018a) . Accordingly, epigenetics has become vital to understanding gene × environment interactions and researchers are increasingly interested in using epigenetic exposureassociated changes as biological markers (Chan & Baylin, 2010; Lockwood, Su & Youssef, 2015; Whayne, 2015; Leygo et al., 2017; Levine et al., 2018) .
(2) Epigenetic biomarkers Even temporary epigenetic changes can influence and compromise cell states (Ladd-Acosta, 2015; Schmidl et al., 2018) . Therefore, epigenetic marks are interesting candidates to link environmental exposure to cell and organismal phenotype alterations through the development of epigenetic biomarkers (Mulero-Navarro & Esteller, 2008; Mirbahai & Chipman, 2014; Ladd-Acosta, 2015; García-Giménez et al., 2017) . Such epigenetic signatures may be useful in the prediction of life health outcomes from a specific early life exposure or, in some cases, even from in utero exposure (Ray, Yosim & Fry, 2014; Marsit, 2015; Laufer et al., 2017; Alvarado-Cruz et al., 2018) . Another interesting feature is the inheritance of epigenetic marks; these offer an inherent and robust biological mechanism by which cells remember previous environmental exposures (Bock, 2009; Blake & Watson, 2016; Schmidl et al., 2018) . Thus, epigenetic 'footprints' can be used to develop biological markers that could inform retrospectively on organismal lifetime exposure, as well as on parental germ cell exposure (Manikkam et al., 2012; Mirbahai & Chipman, 2014; Ly, Chan & Trasler, 2015) .
Among epigenetic mechanisms, DNA methylation (DNAm) has been identified as the most promising mechanism for the development of epigenetic biomarkers as it is currently the best-studied epigenetic mechanism (Andersen et al., 2015; Ladd-Acosta, 2015; Bock et al., 2016) . Biological Reviews (2020) 000-000 © 2020 Cambridge Philosophical Society Fundamental research is still required on the roles of histone modifications and non-coding RNAs, since characterisation of the responses of these two epigenetic mechanisms to external stimuli remains relatively scarce (Bird, 2002; Ladd-Acosta, 2015) . In addition, and as Ladd-Acosta (2015) and Bock et al. (2016) comprehensively discussed, histone tail modification measurements require a large number of cells and rapid DNA-protein cross-linking that reduce their suitability for large-scale population studies; RNA molecules typically degrade quickly following extraction and the quality of RNA in many bio-samples is consistently poor. Nevertheless, some reports do claim the suitability of histone modifications and non-coding RNA as epigenetic biomarkers (e.g. Piletič & Kunej, 2016; .
DNAm is a very stable mechanism, capable of providing reliable measurements from a wide range of biological materials, such as tissue, blood (plasma and serum), sputum, urine, etc., even after long-term storage (Nogueira da Costa & Herceg, 2012; Lorincz, 2014) . In the context of therapeutics and biomarker discovery, methylation assays are easy to perform and automate and, in several cases, concordant methylation alterations have been found in different tissues of the human body (Nogueira da Costa & Herceg, 2012; Masliah et al., 2013; Lorincz, 2014; Miranda-Morales et al., 2017) . From an operational point of view, technologies to measure DNAm marks and patterns are now "reproducible, costefficient and amenable to high-throughput processing" (Ladd-Acosta, 2015, p. 118 ). Furthermore, methylation levels have been measured in a wide range of taxa, revealing that DNAm levels in nature are quantitative (values ranging from 0 to 100%) and thus represent natural measures of exposure (Lorincz, 2014; Ladd-Acosta, 2015) . Importantly, DNAm patterns are known to be conserved across deep phylogenies (Suzuki & Bird, 2008; Sarda et al., 2012; Mendizabal et al., 2014) and the genomic regions that reflect divergence of DNAm between related species seem to be enriched for both tissue and development specialisations Hernando-Herraez et al., 2013; Mendizabal et al., 2014) . DNAm marks hold the potential to inform on both interspecific and intra-specific susceptibility to environmental stressors, as inter-individual susceptibility to several diseases is known to be mediated by epigenetic mechanisms (Baccarelli & Bollati, 2009; Ray et al., 2014; Wüllner et al., 2016; Palumbo et al., 2018) .
Epigenetic signatures fulfil several important criteria for a biomarker. They bear long-term stability and are relatively easy to detect, they are highly selective, and they are sensitive to environmental stressors, providing information about changes in exposure at different times and different concentrations/doses (Chan & Baylin, 2010; Nogueira da Costa & Herceg, 2012; García-Giménez et al., 2017; Prince et al., 2019) . Therefore, epigenetic biomarkers present several advantages compared to other regularly used transcriptional biomarkers (see Section II and Table 1 for an appraisal of these biomarkers): epigenetic biomarkers can be more accurate, specific, stable and easily measured (Chan & Baylin, 2010; Ladd-Acosta, 2015; García-Giménez et al., 2017; Leygo et al., 2017) . Other relative advantages are that: (i) epigenetic marks are accessible in body fluids, avoiding the need for biopsy specimens as sometimes required for the development and monitoring of transcriptional biomarkers; (ii) epigenetic mechanisms are usually involved in the initial stages of disease development, and therefore epigenetic biomarkers have the potential to be better suited than transcriptional biomarkers for early diagnosis; (iii) different stages and types of cancer have unique methylation signatures, and such signatures could be targets in the development of specific and accurate biomarkers to assist in tumour-type evaluation as well as prognosis and disease management (Costa-Pinheiro et al., 2015; García-Giménez et al., 2017; Leygo et al., 2017) . In addition, epigenetic modifications are reversible and potentially useful as therapeutic targets (Kelly, De Carvalho & Jones, 2012; Wong, Qian & Yu, 2017; Miranda-Gonçalves et al., 2018) . It is thus likely that epigenetic biomarkers could contribute to better prediction of the adverse effects of exposure to environmental stressors and that epigenetic exposure-associated changes can also be understood as 'footprints' of past (even historical) environmental exposure (Mirbahai & Chipman, 2014; Ladd-Acosta, 2015; García-Giménez et al., 2017) . Accordingly, epigenetic biomarkers could be an important tool in environmental risk assessment (ERA).
ERA is a framework used worldwide to assess prospectively (with the aim of establishing acceptable regulatory concentrations; see Queirós et al., 2019 for a review) or retrospectively (deciding whether an ecosystem is threatened and/or to guide restoration actions; see e.g. Pereira et al., 2017) the environmental risk of contaminants. ERA is primarily focused on assessing the likelihood of exposure to a given stressor [most frequently chemicals, either of natural origin or following negligent discharge (for example of metals from leaching mine effluents), or intentional discharge following synthesis and use (e.g. emerging contaminants or agrochemicals)] causing harmful effects in an ecosystem and/or to human health, and quantifying the risk associated with such exposures. Two key aspects of ERA are the chemical exposure and hazard potential; both can be assessed independently but, to estimate risk, they must be considered together (SETAC, 2018a,b) . The hazard potential of a chemical is mostly determined by its environmental fate and toxicity, while the exposure potential is largely influenced by chemical properties, including the degree and rates of environmental persistence, bioaccumulation potential and solubility in water (Suter II et al., 2007; SETAC, 2018a) . All these factors can also affect the toxicity, and thus chemical toxicity is best described as the amount (dose) of a chemical needed to cause harm (SETAC, 2018b) . ERA develops over three essential stages: (i) problem formulation (identification of possible risks, effects and sources of bias in the analysis); (ii) characterisation of the stressor and its effects; and (iii) risk characterisation and quantification. All three stages integrate outcomes from chemical, ecological and ecotoxicological evidence, which can be collected under a stepwise protocol Biological Reviews (2020) 000-000 © 2020 Cambridge Philosophical Society Epigenetic biomarkers as risk assessment tools composed of tiers increasing in complexity and resolution (U.S. EPA, 1992; Burton et al., 2002; Menzie, MacDonell & Mumtaz, 2007) . For example, in the collection of ecotoxicological evidence, tier 1 typically involves short-term testing with standard organisms, e.g. the acute toxicity test with Daphnia magna (OECD, 2004) when the assessment is focused on the aquatic compartment, while the following tiers include testing in the longer term focusing on reproductive and population parameters [e.g. chronic toxicity testing with D. magna (OECD, 2008)] or mesocosm studies that assess community changes driven by the stressor [see Queirós et al., 2019 for specific examples of organisms and tests 
6-genes signature (CLC, CPA3, DNASE1L3, IL1B, ALPL, C-X-C motif and CXCR2)
Asthma
Identified a six-gene signature from sputum gene expression that significantly and reproducibly discriminates different inflammatory phenotypes of asthma and prediction of inhaled corticosteroid response. Mihály et al.
Individual genes PGR, MAPT and SLC7A5
Breast cancer
Biomarker candidates were identified in the literature and tamoxifen-resistance genes were tested. The three genes were identified as the most promising prognostic biomarkers in tamoxifen-treated patients. However, the biomarkers were not tested in a clinical validation study. Spira et al. (2007) 80-gene biomarker a Lung cancer Identified an 80-gene biomarker from airway epithelial cells that distinguishes smokers with and without lung cancer, using a training set. Further testing on an independent test set showed an accuracy of 83% (80% sensitive, 84% specific), and additional validation in a set independently obtained from five medical centres (N = 35) showed that the biomarker had 90% sensitivity for stage 1 cancer across all subjects. Fielden, Brennan & Gollub (2007) 37-gene signature a Hepatic tumour induction A novel multigene biomarker capable of predicting the likelihood of non-genotoxic chemicals to induce liver tumours was identified, using hepatic gene expression data from rats treated with one out of 100 structurally and mechanistically diverse non-genotoxic hepatocarcinogens and non-hepatocarcinogens. Independent validation of the signature on 47 test chemicals indicates a sensitivity and specificity of 86% and 81%, respectively. Krishnamurthy et al. (2004) Ink4a/Arf tumour suppressor locus Ageing Examined Ink4a/Arf expression in rodent models of aging, showing that its expression increased in almost all tissues with advancing age. The data obtained suggest that the expression of the Ink4a/Arf tumour suppressor locus is a robust biomarker and possibly an effector of mammalian ageing.
involved in each ERA tier for both the aquatic and the soil compartments]. The tiered process is a time-saving and cost-effective strategy that allows fine-tuned assessments; the decision on whether to progress to the next tier is supported by estimations of an integrated risk value or hazardous potential including the corresponding uncertainty levels (Jensen & Pedersen, 2006; Pereira et al., 2018; SETAC, 2018a) . Regardless of tier, the concentrations eliciting a given measurable biological effect are compared to concentration standards that are not expected to cause harm (Chapman et al., 1997; Chapman, McDonald & Lawrence, 2002; SETAC, 2018a) . In this context, epigenetic biomarkers hold great potential for more precise risk estimates and better risk management, thus improving decision making, through their integration in specific ERA tiers (discussed further in Section V.1). The incorporation of epigenetic biomarkers and other epigenetic data in human health and ecological risk assessment of chemicals is already the subject of research, although their use in practice within a regulatory context remains largely unexplored (Ray et al., 2014; Rozek et al., 2014; EFSA, 2016; Cotea et al., 2017) . This disparity can most likely be attributed to numerous data gaps that need to be filled urgently (Goodman et al., 2010; EFSA, 2016; Shaw et al., 2017) .
Our major aim herein is to review the development of epigenetic biomarkers in human health and environmental arenas, but particularly to discuss the incorporation of such biomarkers in ERA of chemicals. We first summarise the evidence from human studies supporting the use of epigenetic exposure-associated changes as biomarkers of exposure and identify promising research avenues. We then discuss the potential benefits of the use of epigenetic biomarkers in environmental arenas and address key challenges regarding their development in this context. Useful organisms and appropriate sequencing techniques are suggested to stimulate future studies. The incorporation of epigenetic biomarkers and other epigenetic data into ERA frameworks is then comprehensively discussed. In particular, we examine the incorporation of epigenetic biomarkers within the tiered scheme of prospective ERA, and explore a possible role of epigenetic biomarkers in retrospective ERA. In this way, by covering both human health and ecological assessment, critical research gaps are identified and 10 key recommendations made for future research regarding the development of epigenetic biomarkers in a regulatory context.
II. THE PATH TOWARDS UNDERSTANDING EPIGENETIC CHANGES AS BIOMARKERS: EVIDENCE AND PERSPECTIVES FROM MEDICINE
In recent years, scientists have explored the suitability of genetic features as biological markers and such research has typically promoted the development and validation of gene expression-based biomarkers ( Table 1) , so that their application in clinical practice for diagnosis and prognosis of disease is now a reality (Goossens et al., 2015; Clemenceau et al., 2018; Tang et al., 2018) . Perhaps the best example is the use of gene expression profiling as a powerful and costeffective biomarker for the discovery of new disease and drug-response biomarkers (Moffitt et al., 2016; Bikel et al., 2017) . Their practical applications include the identification of responsive patients and prediction of responses to treatment in cancer patients (Barh, 2014; Bikel et al., 2017; Selleck, Senthil & Wall, 2017) . Exposure-induced epigenetic changes have also been demonstrated as promising candidates in the development of powerful and reliable biomarkers of exposure Riedmaier & Pfaffl, 2013; Roth, 2013; Ladd-Acosta, 2015; García-Giménez et al., 2017) .
Epigenetic biomarkers are now at the forefront of clinical medicine ( Table 2 ). Based on epigenetic signatures, several commercial tests for cancer detection are now available. In the future, it is expected that epigenetic biomarkers will have a significant role in the prognosis and diagnosis of disease, the prediction of therapeutic responses and the discovery of therapeutic targets, and will enable the development of innovative personalised therapeutic strategies (Masliah et al., 2013; Coppedè et al., 2014; Lorincz, 2014; Costa-Pinheiro et al., 2015; Zhong, Agha & Baccarelli, 2016) . Furthermore, epigenetic biomarkers are likely to be extremely useful in the human health risk assessment of chemicals (Nogueira da Costa & Herceg, 2012; Coppedè et al., 2014; Lorincz, 2014; Rozek et al., 2014; Dennis et al., 2016; Alvarado-Cruz et al., 2018 ) (see Section V.1). This claim stems from the recognition of consistent links between epigenetic effects and chemical exposure. Research has shown the presence of epigenetic exposure-specific genomic location differences and at least some epigenetic biomarkers are able to classify individuals based on their exposure status (Andersen et al., 2015; Ladd-Acosta, 2015; Liu et al., 2018; van Dongen et al., 2018) . For instance, DNAm signatures for smoking exposure differ according to classification as a current, previous, or never smoker (Joehanes et al., 2016; McCartney et al., 2018; Prince et al., 2019) . Zhang et al. (2014) found dose-response relationships for DNAm levels in blood leukocytes in the locus of the F2RL3 gene: there was an inverse relationship between DNAm levels and the average number of cigarettes smoked per day. In addition, the authors reported a consistent dose-response relationship between methylation at the F2RL3 gene and the time since quitting smoking. Also focusing on blood leukocytes, Wan et al. (2012) were able to identify 15 genomic sites that were significantly associated with current smoking, two sites associated with cumulative smoke exposure and three sites associated with time since quitting smoking. In a review, Ladd-Acosta (2015) noted additional evidence supporting the specificity of DNAm signatures of whole/peripheral blood towards a particular exposure period arising from the lack of complete overlap between sites identified in prenatal versus adult exposure windows for smoking: two of the strongest genomic regions in adults Biological Reviews (2020) 000-000 © 2020 Cambridge Philosophical Society Epigenetic biomarkers as risk assessment tools CpG island methylation analysis in common nevi, dysplastic nevi, primary melanomas, and metastatic melanomas demonstrated that dysplastic nevi were affected by promoter methylation of genes that are frequently methylated in melanoma but not in common nevi. The authors also showed that the CLDN11 gene promoter methylation showed specificity for melanoma, as it occurred in 50% of primary melanomas but in only 3% of dysplastic nevi. A diagnostic algorithm that incorporates methylation of the CLDN11,
Biological Reviews (2020) 000-000 © 2020 Cambridge Philosophical Society Context of the study and reported characteristics of the biomarker(s) CDH11, PPP1R3C, MAPK13 and GNMT genes was validated in an independent set, and helped to distinguish melanoma from dysplastic nevus (AUC = 0.81). Guintivano et al. (2014) Suicide and suicidal behaviour: SKA2
The epigenetic variation associated with suicide and suicidal behaviours was investigated. DNA methylation profiling was employed separately on neuronal and glial nuclei in a discovery set of post-mortem brains and the results were validated with a different set of prefrontal cortical tissue as well as peripheral blood from three living groups. SKA2 was identified as a possible modulator of cortisol suppression and this gene significantly interacted with anxiety and stress to explain about 80% of suicidal behaviour and progression from suicidal ideation to a suicide attempt. Heyn et al. (2013) Breast cancer: DOK7 gene The authors studied whole blood samples from 15 twin pairs for discordant breast cancer marks. High-resolution DNA methylation analysis identified 403 differentially methylated CpG sites, including known and novel, potentially important breast cancer genes. Further validation of the results in an independent cohort (21 twin pairs) determined the docking protein DOK7 as a candidate for blood-based cancer diagnosis. DNA hypermethylation of the promoter region of this gene was seen in primary breast cancer tissues and cancer cell lines years before tumour diagnosis, thus supporting the use of this gene as a powerful epigenetic blood-based biomarker for breast cancer detection. Lind et al. (2011) Colorectal cancer and adenomas: CNRIP1, FBN1, INA, MAL, SNCA and SPG20
Candidate biomarkers were subjected to quantitative methylation analysis in a test set of tissue samples from colorectal cancers, adenomas, and normal colonic mucosa. Findings were further validated in an independent set (523 human samples), which revealed that the promoter's hypermethylation of the six listed genes was frequent in both colorectal cancers (65-94%) and adenomas (35-91%), whereas normal mucosa samples were rarely (0-5%) methylated. The combined sensitivity of at least two positives among the six markers was 94% for colorectal cancers and 93% for adenoma samples, with a specificity of 98%. The resulting AUC-ROC curve values were 0.984 for cancers and 0.968 for adenomas versus normal mucosa, thus supporting the use of this epigenetic biomarker as a suitable option for the early detection of colorectal cancer. Begum et al. (2011) Lung cancer: APC, CDH1, MGMT, DCC, RASSF1A and AIM1
This study analysed the serum aberrant methylation DNA of 15 gene promoters from 10 patients with primary lung tumours. In an independent set, the authors tested the six Biological Reviews (2020) 000-000 © 2020 Cambridge Philosophical Society
Epigenetic biomarkers as risk assessment tools Context of the study and reported characteristics of the biomarker(s) most promising genes (APC, CDH1, MGMT, DCC, RASSF1A and AIM1) for further elucidation of the diagnosis application of this panel of markers, showing that promoter hypermethylation of at least one of these genes was detected in all 10 tumours. In the independent set, using a single gene that had 100% specificity (DCC), 35.5% (95% CI: 25-47) of the 76 lung cancer patients were correctly identified. For patients without methylated DCC, addition of a logistic regression score that was based on the five remaining genes improved sensitivity from 35.5% to 75% (95% CI: 64-84), but decreased the specificity from 100% to 73% (95% CI: 54-88). These results are promising but further testing is required. Kneip et al. (2011) Lung cancer: SHOX2 Based on previous reports claiming that DNA methylation levels of the SHOX2 locus reliably identified lung cancer in bronchial aspirates of patients, this work attempted to develop a modified SHOX2 assay for use in a bloodbased test. DNA methylation of SHOX2 was measured in plasma samples from 411 individuals. A later training study (20 stage IV patients with lung cancer and 20 controls) was performed to show the feasibility of detecting the SHOX2 biomarker in blood and to determine a methylation cutoff for patient classification. The results showed that methylation of SHOX2 could be used as a biomarker to distinguish between malignant lung disease and controls at a sensitivity of 60% (95% CI: 53-67%) and a specificity of 90% (95% CI: 84-94%). Cancer in patients with stages II (72%), III (55%), and IV (83%) was detected at a higher sensitivity when compared with stage I patients. Mulero-Navarro & Esteller (2008) Colon cancer: p16INK4a (Pilsner et al., 2007; Majumdar et al., 2010) . Liu et al. (2018) showed that a number of genomic DNAm sites displayed consistent alcohol-related effects in whole-blood samples of two groups with different ancestries (European and African). The authors identified a set of 144 CpGs for discriminating current heavy alcohol drinkers from non-drinkers, and the lack of similarity of many CpG sites in the transancestry comparison was also noticed.
Remarkably, when applied as biomarkers, these selected CpGs performed better than commonly used clinical variables and biomarkers in discriminating current heavy alcohol drinking. In fact, several studies commented that universal DNAm changes occur in different exposure windows but that many of these are specific for a particular exposure window (Ray et al., 2014; Ladd-Acosta, 2015 ). An increasing number of studies report the use of DNAm data as a robust method to distinguish individuals according to the frequency of their exposure to environmental chemicals and substances (Andersen et al., 2015; van Dongen et al., 2018; Prince et al., 2019) . Perhaps the best example is the study of Shenker et al. (2013b) who built a robust DNAm classifier able to Prostatic cancer: GSTP1 Quantified methylation in the GSTP1 promoter in prostate tissue samples from 69 patients with early-stage prostatic adenocarcinoma and 31 patients with benign prostatic hyperplasia. The authors performed a prospective, blinded investigation to quantify GSTP1 promoter methylation in sextant prostate biopsy specimens from 21 additional patients with elevated serum prostate-specific antigen levels, 11 of whom had histologically identified adenocarcinoma and 10 of whom had no morphological evidence of adenocarcinoma. Results showed that GSTP1 methylation levels accurately discriminate between normal hyperplastic tissue and prostatic carcinoma in small samples of prostate tissue, with the potential to improve the standard pathological/histological assessment of prostate cancer.
AUC-ROC, the common performance measurement area under the curvereceiver operating characteristics; CI, confidence interval.
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Epigenetic biomarkers as risk assessment tools predict former and never smokers (71% sensitivity; area under the curve of 0.83). As a measure of comparison, a commonly used predictive model of smoking exposure that uses cotinine levels showed much poorer performance (area under the curve of 0.47) (Ladd-Acosta, 2015). Despite the valuable insights achieved to date, there are still considerable data gaps concerning the development of epigenetic biomarkers and their incorporation in clinic and risk-assessment frameworks. Further research specifically directed to regulatory frameworks is urgently required, for example to collect dose-response and time-response data (see Section V.2, for a comprehensive discussion). Regarding the clinical application of epigenetic biomarkers, a more detailed mechanistic understanding of the reversibility of epigenetic marks and their persistence over time is required, as well as a better comprehension of the connection of epigenetic marks to changes in gene expression and higher-level effects, i.e. effects on the health of cells/individuals (Goodman et al., 2010; Ray et al., 2014; EFSA, 2016) . Curiously, while methylation of CpG sites in promoter regions is typically correlated with gene expression silencing, it was reported that epigenetic marks in other parts of the genome seem to be correlated with different gene expression patterns (Bell et al., 2011; Ray et al., 2014; Schübeler, 2015) . Furthermore, the validation of findings from rodent models in humans is also a major requirement for a future successful application of epigenetic biomarkers in clinical practice (Goodman et al., 2010; Rozek et al., 2014; Laufer et al., 2017) .
III. POTENTIAL OF ENVIRONMENTAL EPIGENETIC BIOMARKERS
(1) The potential for environmental epigenetic biomarkers
In parallel to advances in medicine, the epigenetic machinery of model species in environmental studies is known to respond to several environmental stressors (Vandegehuchte & Janssen, 2011; Jeremias et al., 2018a; Norouzitallab et al., 2019) . Several experimental studies have now confirmed that epigenetic marks/patterns are inherited in numerous organisms (Jeremias et al., 2018b; Norouzitallab et al., 2019) . Thus, epigenetic biomarkers have great potential in environmental quality assessment.
The acquisition of epigenetically determined phenotypes has been found consistently when a given group of organisms is exposed to a given stressor (Feil & Fraga, 2012; Burggren, 2016) . In this sense, epigenetic mechanisms may help organisms to cope better with environmental challenges. Due to epigenetic inheritance, the epigenetic modulation of populations driven by a given environmental stressor can persist for long periods in an ecosystem, which is likely to be an advantage if the stressor is stable but is likely to be detrimental under fluctuating stressor levels, possibly compromising consecutive generations of a population (Brander, Biales & Connon, 2017; Shaw et al., 2017; Jeremias et al., 2018a) . From an evolutionary perspective, as epigenetic marks/patterns can retain a memory of exposure over several generations, even when exposure no longer occurs, epigenetic mechanisms could be an important driver of local adaptation, conceivably shaping the response of locally adapted populations to new exposure events (Jeremias et al., 2018a) . Accordingly, epigenetics has been increasingly discussed by environmental scientists, and several studies have comprehensively explored the importance of epigenetics in fields such as ecotoxicology, ecology and evolution (Vandegehuchte & Janssen, 2011 Mendizabal et al., 2014; Verhoeven, VonHoldt & Sork, 2016; Chatterjee, Gim & Choi, 2018b) .
Unlike in human health, the development of environmental epigenetic biomarkers is still in its infancy. Nevertheless, there is evidence demonstrating that epigenetic exposureassociated changes in model species share several characteristics with human epigenetic changes. First, the relatively easy detection of epigenetic changes is now a reality in environmental arenas, as a vast array of sequencing techniques is available to measure both genome-wide and site-specific epigenetic changes. This has led to an ever-increasing availability of annotated genomes of vertebrate and invertebrate model species (Kurdyukov & Bullock, 2016; Jeremias et al., 2018a) . Furthermore, and relevant to regulatory contexts, there is increasing evidence that epigenetic exposureassociated changes are specific to the stressor involved (Ray et al., 2014; Vandegehuchte & Janssen, 2014) . In support of this, Artemov et al. (2017) found that the DNAm profile of marine sticklebacks transferred into freshwater partially converged to that of a freshwater stickleback and that the genes encoding ion channels (KCND3, CACNA1FB and ATP4A) were differentially methylated between the freshwater and marine populations. Lighten et al. (2016) compared the transcriptome of two recently diverged populations of the winter skate (Leucoraja ocellata). The authors found that epigenetic mechanisms were responsible for the different gene expression profiles observed in the studied populations, and also showed that a relevant portion of the differentially expressed transcripts was correlated with genes that functioned in the different life-history traits of the populations. In Daphnia magna, a key species in regulatory ecotoxicological assessment, Jeremias et al. (2018b) and Trijau et al. (2018) monitored methylation changes that occurred when organisms were exposed to high salinity levels and chronic γ irradiation, respectively. In the F0 generation challenged with the stressors, both studies detected a hypomethylation pattern of specific genes that was maintained in following generations that were no longer exposed to the stressor (F1, F2 and F3 organisms cultured in the same medium as the controls). Both studies highlighted that the detected hypomethylation pattern seemed to be targeted to genes with key roles in the metabolic response to the challenging stressors. This finding is supported by the results of other experimental studies (Asselman et al., 2015 (Asselman et al., , 2017 Dimond & Roberts, 2016; Weyrich et al., 2016; Kong et al., 2017) . Concordant epigenetic changes and corresponding changes in gene expression have been recorded for several environmentally relevant model species but further research is still required on the connection between exposure and epigenetic changes at the individual and/or population level (see Section V.2). Finally, and also important in the context of the development of environmental biomarkers, true transgenerational epigenetic changes have now been confirmed in numerous environmentally relevant model species (Harris, Bartlett & Lloyd, 2012; Bell & Stein, 2017; Shaw et al., 2017) . A single-generation exposure to a stressor thus is capable of resulting in an epigenetic change that can be maintained over several generations and that can be detected and monitored.
Similartothereasoningusedinhumanhealthfields, exposureassociated DNAm signatures should be useful features for the development of epigenetic biomarkers, which can be used to predict the adverse effects of exposure to different environmental stressors (see Section V.1) (Ray et al., 2014; Suarez-Ulloa, Gonzalez-Romero & Eirin-lopez, 2015; Chatterjee et al., 2018b) . Another interesting but relatively unexplored approach is to look retrospectively for epigenetic exposure-associated changes as 'footprints' of previous (even historical) environmental exposure to chemicals (see Section V.3) (Mirbahai & Chipman, 2014; Ray et al., 2014; Kamstra et al., 2018) . It is likely that epigenetic biomarkers will help to unveil the molecular basis of adaptation to environmental contamination and/or change, allow the earlier detection, the better monitoring of polluted sites and even the identification of new molecular targets for biological remediation (Vandegehuchte & Janssen, 2014; Shaw et al., 2017; Jeremias et al., 2018a) . In this way, it is also expected that epigenetic biomarkers will be a useful resource in the ecological risk assessment of chemicals, despite the data gaps that still exist regarding regulatory aspects (Goodman et al., 2010; Head, Dolinoy & Basu, 2012; Vandegehuchte & Janssen, 2014; Shaw et al., 2017; Chatterjee et al., 2018b) .
(2) Development of environmental epigenetic biomarkers: appropriate model organisms
In environmental quality assessment, research has not yet specifically focused on the development and validation of epigenetic biomarkers. Nevertheless, some studies provide important clues in this context that are worth exploring, as identified relationships between environmental exposure and epigenetic changes can be used to identify candidate biomarkers. We extracted from such studies the species that have been successfully targeted and could be used in future monitoring of site/genespecific DNAm (see Fig. 1 and Table 3 ).
Most studies reporting environmentally induced epigenetic changes that could potentially serve as epigenetic biomarkers, are focused on well-known model organisms. For Arabidopsis thaliana, a model organism in plant biology, environmental stressors are known to determine specific DNAm patterns that can be inherited (Suter & Widmer, 2013; Pikaard & Scheid, 2014; Kooke et al., 2015) . Although several stressor-driven histone modifications have been recorded, this species seems suitable for the study of DNAm changes as environmental biomarkers (Lang, Xie & Zhu, 2016; Wang et al., 2016) . Despite having low levels of DNAm, Drosophila melanogaster also seems a useful system for studying the role of epigenetic mechanisms in various biological processes, such as gene control and developmental programming, as well as the relationship between altered epigenetic patterns and medical disorders (Zhong, 2016; Panikar et al., 2017; Solovev et al., 2018; Guan et al., 2019) . Thus, D. melanogaster may represent a useful resource for the development of DNAm biomarkers and the specific goal of predicting negative biological outcomes on different physiological or metabolic processes as a result of environmental exposure. The agouti mouse has also been shown to be a valuable resource for epigenetic studies in disease and development (Wolff et al., 1998; Dolinoy, 2008; Jirtle, 2014) , and this species may be particularly useful in the development of epigenetic biomarkers that inform on later life health outcomes resulting from prenatal exposures. Another valuable vertebrate model organism is the zebrafish, Danio rerio. This species is commonly used in both the (eco)toxicological and biomedical fields, and could contribute to understanding how environmentally induced epigenetic marks/patterns occurring in different developmental stages influence later life sensitivity to stressors (Dai et al., 2014; Laing et al., 2016; Cavalieri & Spinelli, 2017; Szabo et al., 2017) .
Daphnia and Artemia are two suitable invertebrate candidates: in species of both genera, epigenetic marks that potentially serve as biological markers of exposure have already been identified for several natural stressors (Norouzitallab et al., 2014; Trijau et al., 2018; Jeremias et al., 2018b) . Both have great potential as epigenetic model organisms since there is a very large ecological, ecotoxicological and evolutionary literature available for these species, and clonal populations can be easily established and maintained in the laboratory (Harris et al., 2012; Granada et al., 2018; Norouzitallab et al., 2019) . In addition, draft genome sequences of Daphnia magna and Daphnia pulex are available and their reproductive strategy facilitates transgenerational studies and allows the elimination of genetic variability (Harris et al., 2012; Bell & Stein, 2017; Brander et al., 2017) . Finally, several other organisms have been argued as suitable candidates for the development of epigenetic biomarkers: the fish Chrosomus eos-neogaeus, the honeybee Apis mellifera and the marbled crayfish Procambarus virginalis (Lyko, 2017) (Vogt, 2008; Bonasio, 2015; Mukherjee, Twyman & Vilcinskas, 2015; Leung, Breton & Angers, 2016; Chatterjee et al., 2018b) . There is thus a wide range of potential model organisms covering different ecosystems, habitats and trophic levels, further underlining the potential of environmental epigenetic biomarkers in environmental science. The assignment of additional model organisms for the endorsement of epigenetic biomarkers as ERA tools is recognised as an area for future research attention in Section V.2.
IV. SEQUENCING TECHNIQUES SUPPORTING THE DEVELOPMENT OF DNAm BIOMARKERS
Choosing an appropriate sequencing technique for measuring site/gene-specific epigenetic changes is dependent on Biological Reviews (2020) 000-000 © 2020 Cambridge Philosophical Society Epigenetic biomarkers as risk assessment tools the aim of the study, input material, coverage of the sequencing technique, and cost per sample, as reviewed by Ladd-Acosta (2015) and Kurdyukov & Bullock (2016) (see Table 4 ). Perhaps the most commonly used method to analyse gene-specific methylation changes/levels is wholegenome bisulphite sequencing. Reduced representation bisulfite sequencing (RRBS) (Meissner et al., 2005 ) is a highly efficient and cost-effective variation of bisulphite sequencing, as prior to bisulphite sequencing the DNA is enzymatically digested (methylation-insensitive restriction enzyme), meaning that only enriched CpG regions are sequenced. The technique requires low DNA input and offers flexibility in coverage, which makes it applicable to a wide range of research areas (Carmona et al., 2017) . Interesting variations to this technique are available, such as enhanced reduced representation bisulfite sequencing that allows higher numbers of CpGs in the data generated and increased coverage of all genomic regions interrogated (Garrett-Bakelman et al., 2015) . Another suitable technique is methyl binding domain sequencing (MBD-Seq) that relies on a methyl binding domain (MBD) to capture methylated DNA fragments (Yu et al., 2010; Lan et al., 2011) . The captured DNA methylated fragments are then used in library preparation and sequencing. Variations of this technique are available, such as methyl CpG binding domain ultra-sequencing that allows the detection of cell-type-specific CpG methylation . Site-specific epigenetic changes can also be detected with methylated DNA immunoprecipitation (MeDIP), which is based on the enrichment of methylated DNA using monoclonal antibodies that specifically recognise 5-methylcytidines and/or 5-methylcytosines (Mohn et al., 2009 ). However, DNA must be first denatured into single stranded molecules for further immunoprecipitation and only then can the purified methylated DNA be used for locus-specific sequencing [via polymerase chain reaction (PCR)] (Sørensen & Collas, 2009 ). Finally, there are several variations of methylation-sensitive amplified polymorphism (MSAP) that allow the parallel and direct analysis of DNAm for a high number of sites across the genome (Yaish, Peng & Rothstein, 2014) . A variation of the MSAP approach that involves next generation sequencing and automated data analysis is a suitable option for plant species (Chwialkowska et al., 2017) . Methylation-sensitive amplified fragment length polymorphism (MS-AFLP) is a modification of amplification fragment length polymorphism (AFLP) that is based on DNA restrictive digestion with enzymes; this technique is also used to profile methylation patterns without requiring detailed knowledge of the genome sequence (Fulneček & Kovařík, 2014; Kurdyukov & Bullock, 2016) . Finally, nanopore DNA sequencing may become relevant in this context as this technique allows the identification of methylation directly from native DNA (Schatz, 2017) . In fact, the detection of DNAm and sequencing of the genome can be achieved in the same run, bypassing the need for previous detailed knowledge on the genome sequence (Clarke et al., 2009; Schatz, 2017) . Although several technical aspects remain to be elucidated (e.g. it is still technically challenging to distinguish modified bases from the nanopore signal), it is likely that the commercialisation of these methods will bring the next generation of instruments for measuring epigenetic changes, with even better sensitivity and specificity than those currently available (Clarke et al., 2009; Kurdyukov & Bullock, 2016; Schatz, 2017) . Fig. 1 . Summary diagram highlighting evidence for the development of potential DNA methylation (DNAm) biomarkers for environmental assessment. Specific (regarding the stressor frameworks already addressed and the targets) methylation changes are assumed to indicate more informative biomarkers. Techniques meeting these requirements and the model organisms allowing such an approach are detailed. Stressor and exposure frameworks that have already been successfully used are also highlighted. The information used in this figure is discussed in Section III, with additional details taken from Jeremias et al. (2018a) . ALFP, amplified fragment length polymorphism. 
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Increased levels of heat shock protein 70 (Hsp70) conferred increased tolerance to heat stress and additional resistance to the pathogenic bacteria Vibrio campbellii. These increased levels were observed after exposure of a parthenogenetic population of Artemia sp. to a non-lethal heat shock. The phenotypic traits were transmitted to non-exposed generations and correlated with altered levels of global DNAm and acetylated histones H3 and H4. The methylation levels of Hsp70 genes hold potential for further testing.
Danio rerio
Oestrogenic compounds CpG island DNAm of the vasa gene Cavalieri & Spinelli (2017) Discussed the use of zebrafish for studying how environmental toxicant exposures affect the regulation of epigenetic Biological Reviews (2020) 000-000 © 2020 Cambridge Philosophical Society Epigenetic biomarkers as risk assessment tools 
Exposing one generation (F0) of D. magna to high levels of salinity caused specific methylation patterns that were transferred to the three consequent nonexposed generations (F1, F2 and F3). This was found for the hypomethylation of six protein-coding genes (PAXIP1, DET1 and DDB1, DI09_8p430, DI09_29p250, snRNPG, coq10) with important roles in the organisms' response to environmental change: DNA damage repair, cytoskeleton organization, and protein synthesis. Results indicated that, in this parthenogenetic model system, epigenetic marks can be useful indicators of past or historic pollution.
Drosophila melanogaster
Ageing Methylation levels of several heat shock proteins Solovev et al. (2018) Explored the use of D. melanogaster as a model for investigating traditional pharmacological substances as potential epigenetic therapy candidates, as well as for using high-precision epigenetic engineering tools to target specific sites and/or effector genes/proteins for discovering and developing novel epigenetic therapies. Reviewed the epigenetic mechanisms of ageing and prolongevity in D. melanogaster and established associations between epigenetic enzymes and the molecular/cellular mechanisms of ageing and longevity in this species. Highlighted that Dnmt2 is the only DNA methyltransferase that acts upon cytosine residues and that its overexpression increases lifespan of the flies. Furthermore, noted that the overexpression of Dnmt2 also modulates the expression levels of several small heat shock protein (Hsp)-encoding genes (Hsp22, Hsp23 and Hsp26), which are known to be involved in ageing processes.
V. INCORPORATING EPIGENETIC BIOMARKERS/DATA INTO ERA
(1) The use of epigenetic biomarkers in ERA ERA is a reliable tool to frame decision making regarding the best management strategies for environmental protection and/or remediation Weeks & Comber, 2005; Pereira et al., 2018) . ERA of chemicals (ERAC) is a prospective approach targeting specifically the likelihood of exposure to a given chemical provoking harmful effects in an ecosystem (ecological risk assessment) and/or human health (human health risk assessment) (van Leeuwen & Vermeire, 2007; Suter II, 2016) . While exposure can be characterised in different environmental compartments, harmful effects of a particular chemical(s) can be quantified at different levels of biological organisation (ranging from single cells, individuals and populations to ecosystems), essentially depending on progress through the tiers defined for each ERAC (SETAC, 2018a,b) . The idea of incorporating epigenetic data into ERAC frameworks was triggered by studies on the benefits of merging gene expression data with human health risk assessment frameworks (Aardema & Macgregor, 2002; Thomas et al., 2012; Ray et al., 2014) . This is logical since epigenetic mechanisms have an important role in regulating transcription, largely acting on upstream gene expression, mediating molecular and cellular responses to chemicals (Feil & Fraga, 2012; Coppedè et al., 2014) . Therefore, epigenetic data should be inherently useful to support ERAC frameworks in the prediction of negative biological outcomes in cases of chemical exposure (Fig. 2) (Barros & Offenbacher, 2009; Ho et al., 2012; Ray et al., 2014; Schulte, Whittaker & Curran, 2015) . A key stage for epigenetic biomarkers will thus be the clarification of adverse outcome pathways (AOPs) or AOP networks (comprising several AOPs), increasing the potential to improve mechanistic data from both well-studied and less well-studied chemicals (EFSA, 2016; Cotea et al., 2017; Angrish et al., 2018) . As a key example, Meehan et al. (2018) explored the mechanistic aspects of toxicity pathway responses, modes of action and AOPs for inorganic arsenite and two endocrine-disrupting compounds (vinclozolin and triclosan), revealing how specific changes in the epigenome may mediate the perturbation of target organs including the liver and CD4 + T cells. It is very likely that epigenetic biomarkers/data could contribute to the better characterisation of hazard potential by providing a comprehensive view on the mode of action or mechanism of toxicity and eventually on exposure routes (Mirbahai & Chipman, 2014; Ray et al., 2014; Rozek et al., 2014; Kuppusamy, Kaiser & Wesselkamper, 2015) . It is clear that risk management can benefit from combining classic ecotoxicological approaches with recent molecular and cellular information such as that provided by genetic and epigenetic data; the combination provides a more comprehensive view on chemical hazardous potential (EFSA, 2016; Angrish et al., 2018; Khan, Momtaz & Abdollahi, 2019) . Contributing to this effort, the newly emerging field of toxico-epigenomics (the study of the relationship between epigenetic alterations and adverse cellular outcomes in response to environmental stressors, chemicals, toxins and drugs) will provide important clues to allow the fine tuning of both human health and ecological risk assessment methodologies, hopefully leading to more precise and accurate risk characterisation (Cotea et al., 2017; Lauschke, Barragan & Ingelman-Sundberg, 2018; McCullough & Dolinoy, 2018; Khan et al., 2019) .
A high degree of uncertainty has been found in several cases where traditional ERAC schemes were applied, with these studies reporting that previously 'safe' chemical levels may actually have negative health and environmental The microarray MS-AFLP platform requires two samples per array: the sample to be studied and the reference sample.
Biological Reviews (2020) 000-000 © 2020 Cambridge Philosophical Society Epigenetic biomarkers as risk assessment tools outcomes (Suter II, Barnthouse & O'Neill, 1987; Damalas & Eleftherohorinos, 2011; Zhang et al., 2013; Ray et al., 2014) . For example, Alyea et al. (2012) compared epigenetic data and no observed effect concentration (NOEC) values for 1,3-butadiene exposure of mice. Their results demonstrated that 1,3-butadiene-induced DNAm changes in mice occur at concentrations which are one and almost two orders of magnitude lower than the NOEC and lowest observed effect concentration (LOEC), respectively, for non-neoplastic lesions, which is the most sensitive endpoint for this substance. Therefore, the current guideline values for this chemical do not avoid epigenetic changes, which may indicate that a change in legislation is required if these epigenetic changes induce immediate or longer-term higher-level biological effects (Alyea et al., 2012; Alyea, Gollapudi & Rasoulpour, 2014) . For several other chemicals, the current regulatory guidelines may also not be protective against epigenetic changes, which opens the possibility that negative health/ environmental outcomes could still occur if such epigenetic exposure-associated changes are reflected in gene expression and higher-level (cell/organismal phenotype) alterations (Alyea et al., 2012 (Alyea et al., , 2014 Shaw et al., 2017) . To tackle this question, Shaw et al. (2017) suggested that future epigenetic-based studies appraising contaminant effects should include concentrations lower than the effective concentration (EC)10-20 or LOEC for the organism's most sensitive phenotypic endpoint, as higher concentrations are likely to be already regulated; they noted that epigenetic effects were only tested "at doses equal to or higher than current LOEC and NOEC levels, rendering the data useless for re-evaluating legislative guidelines" (Shaw et al., 2017, p. 9440 ).
Epigenetic biomarkers prospective ERAC
Add epigenetic causes of relevant phenotypic effects to AOPs Predict negative health outcomes of pulse and/or ancestral exposure Despite these specific recommendations and enthusiasm for the use of epigenetics in assessment of environmental risk, it is critical that one frames this new approach realistically following the established guidelines for toxicity screening in ERAC. In this context, epigenetic changes need to be (i) measurable and reproducible; and should translate into (ii) toxic effects at higher organisational levels (e.g. organism, population). If the first condition is not fulfilled, the change is most likely caused by biological or experimental variation rather than reflecting the toxicant challenge. If the second condition is not fulfilled, one must admit that the stressor tested has no meaningful impacts and so the epigenetic change does not need to be considered further in the risk assessment. Data analysis must surely support such evaluations on whether epigenetic changes are significant and relevant to toxicology, and such support should be twofold. First, it needs to be determined whether observed epigenetic modifications truly result from the exposure. Currently, there are number of statistical methodologies available to study epigenetic changes as a consequence of a toxicant challenge. All assume sufficient experimental replication to distinguish true epigenetic modifications appropriately from background variation, but the statistical approach depends on the technique used for the assessmenti.e. global methylation analysis requires different statistics from bisulfite sequencing or histone profiling [see e.g. Teschendorff & Relton, 2018 for the statistical analysis of DNAm data]. Second, once an epigenetic change is considered to be significant, it is necessary to determine whether this change can lead to toxicity at higher levels and thus has relevance to risk assessment. This is the most difficult yet crucial part. Currently, few studies have been able to do this (Li et al., 2012; Costa-Pinheiro et al., 2015; Miozzo, Vaira & Sirchia, 2015) . In our view, the AOP framework as explored above can be easily applied to epigenetic modifications in this context (Angrish et al., 2018) .
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Assuming the significance of epigenetic changes and their effective translation into higher biological levels of organisation, the conceptual incorporation of epigenetic biomarkers into the tiered scheme of ecological risk assessment must be the next consideration. For now, we believe that epigenetic biomarkers can be seen as useful tools to dissect the effects of chemicals and to predict long-term responses, through the development of cost-effective and short-term tests focused on assessing endpoints at the individual level. We recommend the incorporation of epigenetic biomarkers into tier 2 of ERA, as this tier consists mainly of laboratory tests with single model species focusing on classical endpoints such as growth and reproduction (EFSA, 2013 (EFSA, , 2017 Queirós et al., 2019) , but may also consider molecular biomarkers, e.g. oxidative stress biomarkers (Hutchinson & Pickford, 2002; Hutchinson et al., 2006; Lehtonen et al., 2006; Sobus et al., 2011) . Epigenetic biomarkers could also potentially be incorporated into tier 3 of ERA, where more timeconsuming and costly experiments at the population/community level are required, e.g. micro-and mesocosm experiments (Barnthouse, Munns Jr & Sorensen, 2007; Queirós et al., 2019) . Supporting the view that epigenetics may be important at a population/community level, Nilsen et al. (2016) measured global DNAm levels of American alligators (Alligator mississippiensis) from six sites with variable levels of mercury contamination, demonstrating that while global DNAm levels across all locations was weakly associated with increased mercury exposure, there was a robust relationship in animals sampled from more severely contaminated locations. Epigenetic effects due to contaminants also have been documented in human populations, with the decline in global DNAm levels in a Greenlandic Inuit population exposed to high levels of persistent organic pollutants the most iconic example (Rusiecki et al., 2008; Head et al., 2012; Rozek et al., 2014) . Accordingly, it is likely that epigenetic biomarkers will extend their role in risk assessment by supporting the more ecologically realistic assessment expected at a tier-3 level. However, far more research is required on epigenetics effects at a population level.
Due to epigenetic inheritance, environmental contamination can extend its effects over the long term, which may impact ecosystem functions (Shaw et al., 2017; Jeremias et al., 2018a) . So, if an exposure to a given chemical affecting a single generation can have effects on multiple subsequent generations (even when they are not exposed to the stressor), ERAC frameworks should account for the time interval over which exposure effects still act (Vandegehuchte & Janssen, 2011 Shaw et al., 2017) . Unfortunately, very few studies have addressed such considerations. It is not yet clear how much uncertainty this implies for risk assessment frameworks (Ray et al., 2014; Shaw et al., 2017; Jeremias et al., 2018a) . An exception is the study by Shaw et al. (2017) who discussed extensively the implications of epigenetic transgenerational inheritance for ecological risk assessment and proposed a regulatory framework and optimal experimental design to enable transgenerational epigenetic effects to be assessed and incorporated into conventional ecotoxicological testing. In particular, they proposed that epigenetic transgenerational effects should be assessed in tier 5 of ERA, and argued that the need for this tier should be based on previous testing for epigenetic impacts when organisms are exposed to low concentrations affecting the most sensitive phenotypic endpoints, e.g. tier 4-derived NOEC or EC20 (Shaw et al., 2017) . Whether or not this tier 5 is feasible considering the costs involved and the practical requirements of ERA is questionable, but this will depend on the organisation of the ERA scheme adopted by each regulatory agency.
(2) Synthesising key research directions A key objective for future studies towards developing reliable epigenetic biomarkers is to tackle relevant issues for regulation and decision making regarding human and environmental health, thus to place epigenetic biomarkers within the context of ERA frameworks. While meeting regulatory demands and requirements is a straightforward strategy, there are major gaps in knowledge as discussed herein, and recommendations for future research should take this into account. Below, we list 10 key recommendations for future Biological Reviews (2020) 000-000 © 2020 Cambridge Philosophical Society Epigenetic biomarkers as risk assessment tools research regarding the development of epigenetic biomarkers in a regulatory context.
(1) Dose-response and time-response characterisation of the epigenome or candidate epigenetic biomarkers to define the causality and specificity of epigenetic effects for the proper implementation of epigenetic marks in ERAC. Dose-response studies should target doses below protective benchmarks or doses with a rational basis, e.g. EC10/20 and NOEC for studyspecific endpoints or the most sensitive phenotypic endpoints in the tested species. For time-response data, it remains unclear if epigenetic responses vary according to different exposure times, such as in chronic versus pulse exposure scenarios. To tackle this question properly, both short-term and long-term studies are required as the likelihood of epigenetic transgenerational effects may differ between more continuous or pulse exposures. (2) Testing environmentally realistic exposure concentrations should become a priority in epigenetic research. Most literature is focused on recording epigenetic responses to chemicals at high concentrations but understanding the influence of realistic exposure concentrations in the epigenome will be far more important for regulatory purposes, and represents a key step in understanding the usefulness of epigenetic biomarkers as higher tier tools in risk assessment. (3) We should increase experimental replication in epigenetic studies. This will allow assessment of the variable nature of epigenetic responses and their apparent lack of reproducibility in some experimental studies, e.g. discordance in epigenetic responses among different species and sometimes among populations of the same species. (4) General recommendations for future experimental design in epigenetic studies include the development of standardised positive and negative controls and the application of more complex experimental designs, e.g. epigenetic endpoints should be measured not only at the individual level but also at the population level. Such adjustments in experimental design will be important to standardise findings, and thereby enhance the development and validation of epigenetic biomarkers in a regulatory context. (3) The potential of epigenetic biomarkers in retrospective ERA
The implications of developing epigenetic biomarkers for risk assessment are far-reaching. Besides the potential benefits involved in the incorporation of epigenetic biomarkers into the prospective risk assessment of chemicals, they are also likely to have a role in the context of retrospective risk assessment. Epigenetic biomarkers can serve as clues of past exposure (see Fig. 2) , with epigenetic exposure-associated changes acting as 'footprints' of previous environmental exposure to chemicals (Mirbahai & Chipman, 2014; Ray et al., 2014; Kamstra et al., 2018) . It is now well established that environmental causes can determine specific epigenetic changes and that some such changes can be retained throughout an organism's lifetime and, in certain cases, be transmitted across several generations (Shaw et al., 2017; Chatterjee et al., 2018b; Norouzitallab et al., 2019) . Thus, retrospective epigenetic biomarkers may allow us to track historical environmental contamination scenarios and the resilience of communities (a critical feature defining whether an ecosystem is under pressure or has already adapted to the prevailing environmental scenario). There is increasing evidence demonstrating that epigenetic marks and their corresponding phenotypes can be selected over evolutionary time scales (Varriale, 2014; Jeremias et al., 2018a) . Nevertheless, it is still difficult to distinguish whether environmentally induced epigenetic modifications have a protective role (i.e. result in adaptive benefits) or result in deleterious health effects (Mirbahai & Chipman, 2014; Jeremias et al., 2018a) . This is a key topic for the development of retrospective epigenetic biomarkers, as it is important to differentiate the initial epigenetic modifications (usually referred to as driver epigenetic changes), from those changes triggered by a previous change (e.g. tumour development) (Mirbahai & Chipman, 2014) . While the latter could be important in the context of prospective assessment, especially when such epigenetic signatures account for adverse outcomes during the lifetime or in subsequent generations, they are less relevant in the context of retrospective risk assessment. Above all, the development of retrospective epigenetic biomarkers should be primarily focused on epigenetic marks that serve as indicators of exposure (Goodman et al., 2010; Manikkam et al., 2012) . As stated by Mirbahai & Chipman (2014, p. 15) , the search for epigenetic changes useful in retrospective assessment should take into account that "irrespective of whether such changes may be indicative of toxicity per se, the signature has the potential to act as a surrogate for assessment of toxic exposures and other environmental stressors that could manifest as disease through alternative mechanisms for the same agents".
In the context of retrospective ecological assessment, epigenetic signatures can be seen as biosentinels in different exposure contexts. Mirbahai & Chipman (2014) highlighted that epigenetic 'footprinting' could lead to the identification of classes of chemical contaminants to which humans and other organisms have been exposed. Supporting this claim, the authors provided evidence that certain classes of chemicals can induce class-specific alterations to normal DNAm patterns (Mirbahai & Chipman, 2014) . Epigenetic biomarkers can reflect present and/or previous stress exposures throughout an organisms' lifetime, but also inform on parental germ cell exposures, depending on the nature of the exposure and the development stages affected (Manikkam et al., 2012; Ly et al., 2015; Trijau et al., 2018; Jeremias et al., 2018b) . Within this field, several major challenges remain. First, whereas this biosentinel use of epigenetic biomarkers is clear for current exposure scenarios, it is not straightforward to apply it to past exposure that no longer exists or for intermittent exposure scenarios (which both could mean a given ecosystem was susceptible to future impairment in the absence of appropriate management actions). Conceptually, by assessing epigenetic signals at different developmental stages of organisms collected in the ecosystem of interest and integrating this information with that on stressor levels (and typical fluctuation patterns) in the environment, insights could be provided on the prevailing nature of the epigenetic marks. Translocation experiments may also be useful to distinguish whether the epigenetic marks identified reflect past or current exposure, depending on the site grid involved in each retrospective ERA. In this context, it is important to understand how genotypic variability versus environmental pressure account for the epigenetic variability observed; it may be the case that populations exhibit great variability in epigenetic responses rather than presenting clear patterns in response to a given or multiple stressors, impairing the causal links required to support retrospective assessment. Despite this topic being almost unexplored, Berbel-Filho et al. (2019) recently analysed the DNAm patterns of two highly inbred strains of a naturally self-fertilising fish reared in two contrasting environments, in order to understand the obligatory (genotype dependent), facilitated (partially genotype dependent) or pure (genotype independent) nature of epigenetic variation. Their results showed higher methylation differences between genotypes than between environments, suggesting that in some cases genotypes have an overriding influence on DNAm patterns.
In spite of the large amount of research that remains to be done, epigenetic biomarkers are promising as tools in retrospective ERA as they can discriminate exposure and effects in real environmental scenarios (Athanasio et al., 2018; Jeremias et al., 2018a) . The recommendations outlined in Section V.2 will apply here, with the species selected for study being perhaps the most important distinguishing (from ERAC) consideration. Epigenetic models may not be available for use in retrospective ERA depending on the focused ecosystem. To tackle this issue, we should focus on species that are representative of the ecosystem under study, and that Biological Reviews (2020) 000-000 © 2020 Cambridge Philosophical Society Epigenetic biomarkers as risk assessment tools are likely to respond to the suspected stressors. Even if the genome sequence is not available for such species, emerging sequencing technologies that do not require previous knowledge on genomes can support this task (Table 4) . By contrast, in ecosystems where validated model species are available, their use should be prioritised, and particular attention should be given to clonal (genetically identical) models since these can provide a homogenous background (allowing the elimination of genetic variability), to facilitate the detection of epigenetic changes accumulating throughout the life cycle and transmitted from generation to generation as well as facilitating the understanding of their individual/population consequences (Harris et al., 2012; Mirbahai & Chipman, 2014) .
VI. CONCLUSIONS
(1) Epigenetic biomarkers are now at the forefront of human health since epigenetic signatures are potential candidates to link exposure to cell and organismal phenotype alterations. They can be useful to predict and inform on later-life health outcomes from a specific early life exposure and, in some cases, even from in utero exposure.
(2) Due to the mitotic/meiotic inheritance of epigenetic marks across successive generations, epigenetic memory offers a robust biological mechanism for cells to retain a memory of previous environmental exposures.
(3) Despite remaining almost unexplored, the development of epigenetic biomarkers offers unique potential in environmental assessment, including the earlier detection and better monitoring of environmental contaminants. Specifically targeting the development of DNAm biomarkers in environmental sciences, we propose a conceptual strategy that involves monitoring site/gene-specific DNAm changes, highlighting the most suitable organisms and the proper sequencing techniques. (4) By bringing together the fields of epigenetics and ERA in a comprehensive framework to tackle contamination challenges, promising avenues open for scientists and regulators. The incorporation of epigenetic biomarkers into the prospective risk assessments for chemicals should allow the better characterisation of hazard potential (exposure and effects), by providing a comprehensive view of the mode of action or mechanism of toxicity and eventually elucidating exposure routes (thus contributing to the establishment of AOPs). This involves the incorporation of epigenetic biomarkers at least in tier 2 of ERA, although their use in the more ecologically realistic scenarios typical of higher tiers should not be ruled out. (5) Epigenetic biomarkers could also have an important role in retrospective assessment by potentially allowing us to distinguish better between fluctuating or pulse and chronic exposures, as well as providing insights into the resilience of natural populations. (6) Despite their potential, epigenetic endpoints are cur-
rently not yet incorporated into risk assessments, mainly due to the numerous data gaps that still exist in the field. It is hoped that more targeted research and improved knowledge focusing on regulatory aspects will allow epigenetic biomarkers/data to become a key asset for improving human health and ecological risk assessment frameworks by allowing more reliable risk characterisation, and therefore will contribute to improved decision making regarding environmental protection or recovery.
VII. ACKNOWLEDGEMENTS
Thanks are due to FCT/MCTES for financial support to CESAM (UID/AMB/50017/2019) through national funds. G.J. was the recipient of an individual FCT (SFRH/ BD/139076/2018) research grant. J.L.P. is funded by National Funds through FCT, in the scope of the framework contract foreseen in article 23 of the Decree-Law 57/2016 changed by Law 57/2017. J.A. is a postdoctoral fellow of the Science Foundation Flanders (FWO Vlaanderen) and was the recipient of an individual research grant from FWO (1521617N). We are grateful to an anonymous reviewer, whose constructive comments and reasoning greatly contributed to the improvement of this manuscript, as well as to the Assistant Editor for helpful suggestions that contributed to improved clarity and conciseness. 
VIII. REFERENCES
